CLINICAL_TRIALS
trial_result
· 2023-12-05
Clinical Trial Update: A Study of CCX140-B in Subjects With FSGS [Phase 2]
Summary
Phase 2 trial of CCX140-B in subjects with focal segmental glomerulosclerosis has completed, with results posted in December 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: FSGS, Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2023-12-05